Building on this evidence of broad cardiovascular effects, recent evidence from a comprehensive meta-analysis suggests SGLT2 inhibitors may reduce the risk of atrial fibrillation, which is particularly relevant given that patients with T2DM have a 40% increased risk of developing atrial fibrillation and its associated complications including stroke and heart failure [14]. This evidence concerns the gene SLC5A2 and heart failure.